Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P10 vs Rituxan vs MabThera in Rheumatoid Arthritis
NCT02149121Phase 3Completed
- Sponsor
- Celltrion
- Start
- Aug 2014
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (3 arms), sponsored by Celltrion. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 24 weeks, Area Under the Concentration-Time Curve From Time Zero to Infinity at 24 weeks and 2 more. Started Aug 2014; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02149121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02149121.